Taking SCLC on a Bad LSD(1) Trip One NOTCH Further

Jun Kim; Julien Sage

doi:10.1016/j.molmed.2019.02.009

Taking SCLC on a Bad LSD(1) Trip One NOTCH Further

Trends Mol Med. 2019 Apr;25(4):261-264. doi: 10.1016/j.molmed.2019.02.009. Epub 2019 Mar 6.

Authors

Jun Kim¹, Julien Sage²

Affiliations

¹ Department of Pediatrics, Stanford University, Stanford, CA 94305, USA; Department of Genetics, Stanford University, Stanford, CA 94305, USA.
² Department of Pediatrics, Stanford University, Stanford, CA 94305, USA; Department of Genetics, Stanford University, Stanford, CA 94305, USA. Electronic address: julsage@stanford.edu.

Abstract

Small cell lung cancer (SCLC) is an aggressive form of lung cancer for which therapeutic options are very limited. A new study (Augert et al. Sci. Signal. 2019;12:eaau2922) shows that inhibition of the LSD1 demethylase can induce derepression of NOTCH receptor genes and subsequent activation of the NOTCH pathway, potently suppressing the growth of SCLC.

Keywords: ASCL1; LSD1; NOTCH; SCLC; epigenetics; neuroendocrine.

Publication types

Letter

MeSH terms

Basic Helix-Loop-Helix Transcription Factors / metabolism
Histone Demethylases / metabolism*
Humans
Lung Neoplasms / etiology*
Lung Neoplasms / metabolism*
Protein Binding
Receptors, Notch / metabolism*
Signal Transduction*
Small Cell Lung Carcinoma / etiology*
Small Cell Lung Carcinoma / metabolism*

Substances

ASCL1 protein, human
Basic Helix-Loop-Helix Transcription Factors
Receptors, Notch
Histone Demethylases
KDM1A protein, human

Grants and funding

R01 CA201513/CA/NCI NIH HHS/United States